Article
Immunology
Michelle A. Kendall, Umesh Lalloo, Courtney Fletcher, Xingye Wu, Anthony T. Podany, Sandra W. Cardoso, Prudence Ive, Constance A. Benson
Summary: This study investigated the safety and pharmacokinetics of protease inhibitor-based antiretroviral therapy in combination with rifampin or rifabutin for HIV and TB co-infected patients in resource-limited settings. The results showed that double-dose lopinavir/ritonavir with rifampin and lopinavir/ritonavir with rifabutin had acceptable safety profiles and tuberculosis outcomes, although HIV suppression rates were suboptimal. Further research is needed to explore the rapid clearance of rifabutin and low C-max levels in some participants.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Toxicology
Julie Nilles, Johanna Weiss, Max Sauter, Walter E. Haefeli, Stephanie Ruez, Dirk Theile
Summary: Compared to standard doses of rifampicin, standard doses of rifabutin have a lower risk of drug-drug interactions. Rifabutin has weaker cellular uptake, less activation of the nuclear receptor, and less impact on gene expression and activity. Additionally, rifabutin is a potent inhibitor of Pgp.
ARCHIVES OF TOXICOLOGY
(2023)
Article
Immunology
Tiankuo Yang, Bowen Liu, Junpeng Zhou, Yalin Shen, Xiaona Song, Xiaoqiong Tang, Mohammed Benghezal, Barry James Marshall, Hong Tang, Hong Li
Summary: Rifabutin showed no cross-resistance with other rifamycins in Helicobacter pylori. Using rifampicin E-test strips to predict rifabutin resistance in H. pylori is deemed inappropriate based on this study's findings.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Toxicology
Lottida Phondeth, Rajamanikkam Kamaraj, Julie Nilles, Johanna Weiss, Walter E. Haefeli, Petr Pavek, Dirk Theile
Summary: This study demonstrates that rifabutin can partially mask P-gp induction by binding to the inhibitory site of P-gp with high affinity.
ARCHIVES OF TOXICOLOGY
(2023)
Article
Pharmacology & Pharmacy
Aida N. N. Kawuma, Roeland E. E. Wasmann, Kelly E. E. Dooley, Gary Maartens, Paolo Denti
Summary: Rifabutin may serve as an alternative to rifampicin in co-administration with dolutegravir, as it does not require dose adjustment and can achieve the desired drug concentration.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Microbiology
Vianney Tuloup, Mathilde France, Romain Garreau, Nathalie Bleyzac, Laurent Bourguignon, Michel Tod, Sylvain Goutelle
Summary: Rifamycins such as rifampicin and rifabutin are commonly used to treat mycobacterial and staphylococcal infections. Drug-drug interactions caused by rifampicin are more potent than those caused by rifabutin, even with sensitive cytochrome P450 substrates.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Infectious Diseases
Xiaoqin Le, Xiaoye Guo, Jianjun Sun, Li Liu, Yinzhong Shen, Jiangrong Wang, Tangkai Qi, Zhenyan Wang, Yang Tang, Wei Song, Lin Yin, Lijun Zhang, Renfang Zhang, Jun Chen
Summary: This study evaluated the pharmacokinetics of dolutegravir in HIV/TB or MAC co-infected patients treated with rifampicin or rifabutin. The results showed slightly higher concentrations of dolutegravir in the rifampicin group compared to the non-TB/MAC group, while lower concentrations were observed in the rifabutin group. Therefore, the once-daily regimen of dolutegravir with rifabutin can only serve as an alternative option for HIV/TB or MAC co-infected patients.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Microbiology
Jiaqi Cheng, Jun Yan, Zeferino Reyna, Matt Slarve, Peggy Lu, Brad Spellberg, Brian Luna
Summary: The study found that rifabutin and colistin showed synergistic effects in combating Acinetobacter baumannii, with low-dose colistin significantly suppressing the emergence of rifabutin resistance. This combination presents a promising therapeutic option for highly resistant A. baumannii infections.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Microbiology
Ming-Chih Yu, Ching-Sheng Hung, Chun-Kai Huang, Cheng-Hui Wang, Yu-Chih Liang, Jung-Chun Lin
Summary: Drug resistance in Mycobacterium tuberculosis is a global health issue, and traditional methods for detecting resistance are time-consuming and inefficient. In this study, a whole-genome sequencing pipeline using the Nanopore MinION platform was developed to diagnose drug-resistant MTB isolates more accurately and quickly.
MICROBIOLOGY SPECTRUM
(2022)
Review
Pharmacology & Pharmacy
Vincent Trebosc, Christian Kemmer, Sergio Lociuro, Marc Gitzinger, Glenn E. Dale
Summary: Rifamycin antibiotics, particularly rifampicin, are crucial in treating TB and Gram-positive infections. Rifabutin, another rifamycin antibiotic, shows potent activity against the important Gram-negative pathogen Acinetobacter baumannii by hijacking its iron uptake system. There is a need for the development of an intravenous formulation of rifabutin, BV100, for the treatment of difficult-to-treat carbapenem-resistant A. baumannii infections.
DRUG DISCOVERY TODAY
(2021)
Article
Microbiology
Elisa H. Ignatius, Mahmoud Tareq Abdelwahab, Bronwyn Hendricks, Nikhil Gupte, Kim Narunsky, Lubbe Wiesner, Grace Barnes, Rodney Dawson, Kelly E. Dooley, Paolo Denti
Summary: Shorter, more potent regimens are needed for tuberculosis, and pretomanid offers potential as a treatment-shortening agent. However, it remains unclear how pretomanid interacts with key first-line drugs like rifampin and whether concurrent use may impact its efficacy.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Infectious Diseases
Ma-Chao Li, Xiao-Yue Wang, Tong-Yang Xiao, Shi-Qiang Lin, Hai-Can Liu, Cheng Qian, Da Xu, Gui-Lian Li, Xiu-Qin Zhao, Zhi-Guang Liu, Li -Li Zhao, Kang-Lin Wan
Summary: This study assessed the relationship between variant rpoB mutations and the degree of rifampin/rifabutin resistance in Mycobacterium tuberculosis. The results revealed that certain mutations were associated with resistance to both drugs, while others were only associated with rifampin resistance. Interestingly, some isolates showed resistance to rifampin but susceptibility to rifabutin.
INFECTION AND DRUG RESISTANCE
(2022)
Article
Microbiology
Miranda Monk, Ramy Elshaboury, Alexander Tatara, Sandra Nelson, Monique R. Bidell
Summary: This case series evaluates the clinical outcomes of using rifabutin instead of rifampin for adjunctive management of staphylococcal hardware-associated infections. The study findings suggest a potential link between rifabutin use and infection recurrence, as well as possible treatment-associated adverse effects.
MICROBIOLOGY SPECTRUM
(2022)
Review
Gastroenterology & Hepatology
Rachel Gingold-Belfer, Yaron Niv, Zohar Levi, Doron Boltin
Summary: Rifabutin triple therapy shows certain efficacy in treating Helicobacter pylori infection as rescue treatment and in first-line treatment, especially in Asian populations. The overall rate of adverse effects is 24.8%, with no significant difference between the treatment group and control group.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Ji Sun Lee, Yunmoon Oh, Hyung Sik Kim, Sungpil Yoon
Summary: The cytotoxicity of various antibiotics was evaluated in drug-resistant cancer cells, and it was found that low doses of rifabutin significantly increased the cytotoxicity of certain antimitotic drugs by inhibiting P-gp. This suggests that repositioning rifabutin for P-gp-overexpressing resistant cancer could be a potential treatment option.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
